Literature DB >> 31478653

Transient-State Analysis of Human Isocitrate Dehydrogenase I: Accounting for the Interconversion of Active and Non-Active Conformational States.

Joseph V Roman1, Trevor R Melkonian2, Nicholas R Silvaggi2, Graham R Moran1.   

Abstract

Human isocitrate dehydrogenase 1 (HsICDH1) is a cytoplasmic homodimeric Mg(II)-dependent enzyme that converts d-isocitrate (D-ICT) and NADP+ to α-ketoglutarate (AKG), CO2, and NADPH. The active sites are formed at the subunit interface and incorporate residues from both protomers. The turnover number titrates hyperbolically from 17.5 s-1 to a minimum of 7 s-1 with an increasing enzyme concentration. As isolated, the enzyme adopts an inactive open conformation and binds NADPH tightly. The open conformation displaces three of the eight residues that bind D-ICT and Mg(II). Enzyme activation occurs with the addition of Mg(II) or D-ICT with a rate constant of 0.12 s-1. The addition of both Mg(II) and D-ICT activates the enzyme with a rate constant of 0.6 s-1 and displaces half of the bound NADPH. This indicates that HsICDH1 may have a half-site mechanism in which the active sites alternate in catalysis. The X-ray crystal structure of the half-site activated complex reveals asymmetry in the homodimer with a single NADPH bound. The structure also indicates a pseudotetramer interface that impedes the egress of NADPH consistent with the suppression of the turnover number at high enzyme concentrations. When the half-site activated form of the enzyme is reacted with NADP+, NADPH forms with a rate constant of 204 s-1 followed by a shift in the NADPH absorption spectrum with a rate constant of 28 s-1. These data indicate the accumulation of two intermediate states. Once D-ICT is exhausted, HsICDH1 relaxes to the inactive open state with a rate constant of ∼3 s-1.

Entities:  

Year:  2019        PMID: 31478653     DOI: 10.1021/acs.biochem.9b00518

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  4 in total

Review 1.  Isocitrate dehydrogenase gene variants in cancer and their clinical significance.

Authors:  Thomas Cadoux-Hudson; Christopher J Schofield; James S O McCullagh
Journal:  Biochem Soc Trans       Date:  2021-12-17       Impact factor: 5.407

2.  Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.

Authors:  Ingvild C Hvinden; Patrick Rabe; Raphael Reinbold; Ryan A Herold; Alina Finch; James Wood; Melissa Morgan; Maximillian Staudt; Ian J Clifton; Fraser A Armstrong; James S O McCullagh; Jo Redmond; Chiara Bardella; Martine I Abboud; Christopher J Schofield
Journal:  Nat Commun       Date:  2022-08-15       Impact factor: 17.694

3.  Exploiting Electrode Nanoconfinement to Investigate the Catalytic Properties of Isocitrate Dehydrogenase (IDH1) and a Cancer-Associated Variant.

Authors:  Ryan A Herold; Raphael Reinbold; Clare F Megarity; Martine I Abboud; Christopher J Schofield; Fraser A Armstrong
Journal:  J Phys Chem Lett       Date:  2021-06-25       Impact factor: 6.475

4.  Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1.

Authors:  Martine I Abboud; Tobias John; Shuang Liu; Victor Mikhailov; Ingvild Hvinden; John Walsby-Tickle; Xiao Liu; Ilaria Pettinati; Tom Cadoux-Hudson; James S O McCullagh; Christopher J Schofield
Journal:  Commun Biol       Date:  2021-11-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.